<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04705909</url>
  </required_header>
  <id_info>
    <org_study_id>2020 - 176</org_study_id>
    <nct_id>NCT04705909</nct_id>
  </id_info>
  <brief_title>Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer</brief_title>
  <official_title>Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Different modalities for breast cancer treatments have exhausting and distressing side&#xD;
      effects and toxicities leading to decreased compliance. Thus, repurposing drugs with accepted&#xD;
      safety profile and possible antitumor activity becomes an eminent constraint.&#xD;
&#xD;
      Statins have been reported to have possible advantages as anticancer, and control of cancer&#xD;
      progression. Moreover, they can sensitize cancer cells for radiotherapy. Therefore, the&#xD;
      investigators aim to investigate the effect of (pitavastatin) added to conventional&#xD;
      chemotherapy protocols for breast cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical response rate</measure>
    <time_frame>6 months</time_frame>
    <description>Response to preoperative therapy as per ultrasonographic tumor size assessment. A responder will have &gt; 50% decrease in the size of the primary tumor without appearance of new lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative reduction of Ki67 in tumor samples</measure>
    <time_frame>6 months</time_frame>
    <description>It will be described as average pre-post differences in percent positive cells with 95% Wilson confidence intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in Cyclin D1 (candidate marker associated with breast tumor proliferation)</measure>
    <time_frame>Baseline up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in Cleaved caspase-3 (CC3) (candidate marker associated with tumor apoptosis)</measure>
    <time_frame>Baseline up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Pitavastatin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For the intended neoadjuvant treatment period, participants will receive -in addition to standard chemotherapy protocol - Pitavastatin tablets 2 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>For the intended neoadjuvant treatment period, participants will receive -in addition to standard chemotherapy protocol - Placebo tablets matching pitavastatin orally once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <description>Pitavastatin 2 mg oral tablets daily will be given to the patients concomitantly with the intended chemotherapy protocol for the treatment period prior to surgery.</description>
    <arm_group_label>Pitavastatin group</arm_group_label>
    <other_name>HMG CoA reductase inhibitor &quot; Lipovastatin&quot;</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>patients in this group will receive placebo tablets concomitantly with the intended chemotherapy for the treatment period prior to surgery.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of informed consent before any study-specific procedures.&#xD;
&#xD;
          -  Histologic confirmation of invasive breast cancer.&#xD;
&#xD;
          -  Plans for the administration of neoadjuvant chemotherapy.&#xD;
&#xD;
          -  Not currently pregnant during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe gastrointestinal disorder&#xD;
&#xD;
          -  Current use of statins or fibrates for any time during the 3 months before the study&#xD;
&#xD;
          -  Proven hypersensitivity to statins&#xD;
&#xD;
          -  Currently on medication for hypercholesterolemia&#xD;
&#xD;
          -  Strong Cytochrome P450 3A4 (abbreviated CYP3A4) (e.g., clarithromycin, HIV protease&#xD;
             inhibitors, and itraconazole), given potential interactions with statins&#xD;
&#xD;
          -  Renal impairment with a creatinine &gt; 1.4 mg/dl&#xD;
&#xD;
          -  Hepatic impairment: Aspartate transaminase (AST)/(SGOT), Alanine Transaminase&#xD;
             (ALT)/(SGPT) ≥ 2.5 x upper limit of the normal range (ULN), OR Total bilirubin ≥ 1.5 x&#xD;
             ULN (subjects with Gilbert's syndrome can have bilirubin of up to 1.5 x ULN), OR&#xD;
             Alkaline phosphatase &gt; 2.5 x ULN&#xD;
&#xD;
          -  Central nervous system (CNS) diseases and major psychiatric diseases or inability to&#xD;
             comply with the protocol procedures&#xD;
&#xD;
          -  Active infections&#xD;
&#xD;
          -  Cardiac failure, class I-IV&#xD;
&#xD;
          -  Current anticoagulant or antiplatelet aggregation therapy&#xD;
&#xD;
          -  Current lactation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Samar A Dewidar, bachelor</last_name>
    <phone>01558333468</phone>
    <phone_ext>002</phone_ext>
    <email>s.dewidar@mans.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Omar H Abdelaleem, PHD</last_name>
    <phone>01003526752</phone>
    <phone_ext>002</phone_ext>
    <email>omarhamdy87@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of pharmacy, Mansoura university</name>
      <address>
        <city>Mansoura</city>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Amal M. Elgayar, professor</last_name>
      <phone>01005157096</phone>
      <phone_ext>002</phone_ext>
      <email>elgayaramal@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Amal M. Elgayar, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed El tantawy, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Moetaza M. Soliman, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>January 9, 2021</last_update_submitted>
  <last_update_submitted_qc>January 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Omar Hamdy</investigator_full_name>
    <investigator_title>Lecturer of Surgical oncology, Principal Investigator, Surgery department.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pitavastatin</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

